
A Phase 1/2 clinical trial assessed the "Sputnik V" vaccine in adolescents aged 12-17, using reduced doses. Both doses were well-tolerated, with no severe adverse events. The 1/5 dose induced stronger immune responses, including cross-neutralization of Delta and Omicron variants. The study emphasizes safety and efficacy in young individuals.
Like
Save
Share